Insider Selling: CytomX Therapeutics (NASDAQ:CTMX) CEO Sells $763,780.98 in Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX) CEO Sean Mccarthy sold 118,969 shares of the business’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total value of $763,780.98. Following the sale, the chief executive officer owned 1,078,922 shares of the company’s stock, valued at approximately $6,926,679.24. The trade was a 9.93% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

CytomX Therapeutics Stock Down 6.9%

Shares of CTMX opened at $4.45 on Friday. The stock’s fifty day simple moving average is $5.28 and its 200-day simple moving average is $4.13. The firm has a market capitalization of $757.35 million, a PE ratio of -111.25 and a beta of 2.44. CytomX Therapeutics, Inc. has a 12-month low of $0.40 and a 12-month high of $8.21.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Monday, March 16th. The biotechnology company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The firm had revenue of $0.66 million during the quarter, compared to analyst estimates of $7.33 million. CytomX Therapeutics had a negative return on equity of 19.77% and a negative net margin of 22.79%. Analysts anticipate that CytomX Therapeutics, Inc. will post -0.05 EPS for the current year.

Analyst Upgrades and Downgrades

CTMX has been the topic of a number of recent analyst reports. Cantor Fitzgerald raised their target price on CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. HC Wainwright boosted their target price on CytomX Therapeutics from $10.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, March 16th. Jefferies Financial Group raised their price target on CytomX Therapeutics from $8.00 to $16.00 and gave the stock a “buy” rating in a research report on Wednesday. Wedbush lifted their price target on shares of CytomX Therapeutics from $6.00 to $11.00 and gave the company an “outperform” rating in a research note on Tuesday, March 17th. Finally, Piper Sandler raised their price objective on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, CytomX Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $13.22.

Trending Headlines about CytomX Therapeutics

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Multiple high‑profile analyst upgrades and big price‑target increases (Jefferies, Barclays, Guggenheim, Wedbush and others) have pushed positive momentum and attracted buyers. Jefferies raises price target to $16
• Positive Sentiment: Trading volume spiked after the analyst upgrade cycle, suggesting the upgrades translated into real buying interest rather than just headlines. Strong trading volume after upgrades
• Neutral Sentiment: CytomX priced an equity offering to raise about $234 million, which materially extends runway and funding for the pipeline but will dilute existing shareholders. Timing and use of proceeds will determine the net effect. Equity offering announcement
• Neutral Sentiment: Short‑interest reports in recent filings show effectively zero reported short interest (data appears inconsistent/NaN), so short positioning is not clearly driving moves at this time. Short interest data (reporting)
• Negative Sentiment: CytomX missed Q1/quarterly estimates on both EPS and revenue, a concrete near‑term negative that increases uncertainty around execution and near‑term cash generation. Shares down on disappointing earnings
• Negative Sentiment: An analyst cut the Q1 EPS forecast, adding to concerns about near‑term financial performance and guidance. Q1 EPS forecast decreased
• Negative Sentiment: Clustered insider selling on March 17 (CEO Sean McCarthy, CFO Christopher Ogden, SVP Marcia Belvin and others) — sizable block sales by multiple senior executives — is dampening sentiment even if some sales are routine. Insider sales report
• Negative Sentiment: Some sell‑side and independent commentary warn that early clinical data may not yet justify elevated valuations, which could pressure momentum traders and cap further upside until clearer clinical/corporate catalysts arrive. Valuation caution commentary

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. bought a new stake in CytomX Therapeutics in the first quarter valued at approximately $39,000. Woodline Partners LP bought a new position in shares of CytomX Therapeutics in the first quarter valued at about $1,054,000. Geode Capital Management LLC lifted its position in CytomX Therapeutics by 103.4% during the second quarter. Geode Capital Management LLC now owns 1,745,176 shares of the biotechnology company’s stock worth $3,963,000 after acquiring an additional 887,218 shares during the last quarter. Franklin Resources Inc. acquired a new position in shares of CytomX Therapeutics in the second quarter valued at approximately $13,096,000. Finally, XTX Topco Ltd bought a new position in shares of CytomX Therapeutics during the second quarter worth approximately $277,000. Institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.